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ABSTRACT
Background
Sickle cell disease is the most common single gene disorder and the commonest haemoglobinopathy found with high prevalence in
many populations across the world. Management of dental complications in people with sickle cell disease requires special consideration
for three main reasons. Firstly, dental and oral tissues are affected by the blood disorder resulting in several oro-facial abnormalities.
Secondly, living with a haemoglobinopathy and coping with its associated serious consequences may result in individuals neglecting
their oral health care. Finally, the treatment of these oral complications must be adapted to the systemic condition and special needs of
these individuals, in order not to exacerbate or deteriorate their general health.
Guidelines for the treatment of dental complications in this population who require special care are unclear and even unavailable in
many aspects. Hence this review was undertaken to provide a basis for clinical care by investigating and analysing the existing evidence
in the literature for the treatment of dental complications in people with sickle cell disease.
Objectives
To assess methods of treating dental complications in people with sickle cell disease.
Search methods
We searched the Cochrane Haemoglobinopathies Trials Register, compiled from electronic database searches and handsearching of
journals and conference abstract books.
Date of last search: 11 April 2016.
Additionally, we searched nine online databases (PubMed, Google Scholar, ClinicalTrials.gov, WHO International Clinical Trials
Registry Platform, Literature in the Health Sciences in Latin America and the Caribbean database, African Index Medicus, Index
Medicus for South East Asia Region, Index Medicus for the Eastern Mediterranean Region, Indexing of Indian Medical Journals). We
also searched the reference lists of relevant articles and reviews and contacted haematologists, experts in fields of dentistry, organizations,
pharmaceutical companies and researchers working in this field.
Date of last search: 03 March 2016.
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Selection criteria
We searched for published or unpublished randomised controlled studies of treatments for dental complications in people with sickle
cell disease.
Data collection and analysis
Two review authors intended to independently extract data and assess the risk of bias of the included studies using standard Cochrane
methodologies; however, no studies were identified for inclusion in the review.
Main results
No randomised controlled studies were identified.
Authors’ conclusions
This Cochrane review did not identify any randomised controlled studies assessing interventions for the treatment of dental complications in people with sickle cell disease. There is an important need for randomised controlled studies in this area, so as to identify the
most effective and safe method for treating dental complications in people with sickle cell disease.

PLAIN LANGUAGE SUMMARY
Treatment of dental complications in sickle cell disease
Review question
We planned to review the evidence regarding the treatment of dental complications in people with sickle cell disease.
Background
Sickle cell disease is a blood disorder which affects at least 5.2% of the world population across a large number of countries. In this
condition, a genetic defect means that the haemoglobin in the red blood cells is not normal, instead the blood cells become sickleshaped and not a normal disc shape. These cells become trapped in blood vessels of various organs, especially during stressful events like
a lack of oxygen, dehydration, extreme temperatures, stress, menstruation and infection. Blocked blood vessels lead to sudden episodes
of severe pain in the short term and chronic organ damage in the long term.
Sickle cell disease also leads to changes and complications in the mouth, jaw and facial areas. Management of these dental complications
is often neglected as people with sickle cell disease focus all their energy on maintaining their general health due to the serious blood
disorder. Neglecting minor dental health issues under these circumstances not only worsens the problem but may also cause a painful
sickle-cell crisis, leading to emergency hospital admissions. Treatment of oral complications in this group of people needs to be tailored
around their blood disorder, in order not to cause any further deterioration to their general health.
There is a lack of information on the appropriate treatment for dental complications in people with sickle cell disease,with no clear
guidelines available. This often results in many people being refused treatment by dentists due to a fear of complications. Hence, we
planned to investigate this issue and make any evidence in this area available to healthcare providers and people with the disease.
Search date
The evidence is current to: 03 March 2016.
Study characteristics
We were not able to find any randomised controlled studies assessing treatment for any dental complications in people with sickle cell
disease.
Key results
No studies were identified, so we can not draw any conclusions or highlight any implications for practice. Studies are needed to establish
the best treatment for dental problems in people with sickle cell disease.

Quality of the evidence
Treatment of dental complications in sickle cell disease (Review)
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There is no evidence from studies (where people are given one treatment or another completely at random) for any treatment for dental
complications in people with sickle cell disease.

BACKGROUND
For an explanation of terms, please refer to the glossary (Appendix
1).

Description of the condition
Problems in oral and dental health commonly experienced by most
individuals result from chronic, degenerative, pathological changes
accompanied by intermittent, recurrent, acute episodes in dental tissues and supporting structures. As dental health problems
are not life-threatening, both individuals and non-oral healthcare
providers consider these a minor inconvenience and the changes
in behaviour required to deal with them as trivial. Fear of dental
treatment and the expense which treatment incurs play a further
inhibitory role among those seeking treatment for dental complications. In turn, this has significant social, functional and economic costs as seen in the 1981 National Health Interview Survey
in the USA, where 4.87 million dental conditions caused 17.7
million days of restricted activity, 6.73 million days of bed disability, and 7.05 million days of work loss (Reisine 1985). People
dealing with more pressing and life-threatening medical conditions, such as haemoglobinopathies, may not regard oral health as
a priority and in some cases may completely neglect it, especially
those from low socio-economic status groups. This often results
in such people arriving in hospital emergency departments with
dental complications and may warrant further hospital admission
to manage associated complications (Laurence 2013).
Haemoglobinopathies are a group of autosomal recessive disorders
affecting the structure and synthesis of haemoglobin. Mutations
in the genes of these chains give rise to conditions such as sickle
cell disease (SCD) and the thalassaemias. This review will focus
on SCD which is one of the most common haemoglobin disorders as well as one of the most common single-gene disorders in
the world (Colledge 2010; Fonseca 2007). Haemoglobinopathies
were previously highly region-specific with a predilection amongst
African, Mediterranean, Middle-Eastern, South-East Asian and
Indian subcontinental groups. However, widespread global migration has resulted in them affecting at least 5.2% of the global
population. Annually there are over 332,000 affected conceptions
or births, of which 275,000 are affected by SCD requiring early
diagnosis and prophylaxis (Modell 2008).
Sickle cell disease comprises a group of clinically significant qualitative haemoglobin (Hb) disorders, in which the sickle gene is

inherited from at least one parent. The sickle mutation itself is the
result of a single base change (GAT→ GTT) in the sixth codon
of exon 1 of the β-globin gene on short arm of chromosome 11,
responsible for the synthesis of the β-globin polypeptide of the Hb
molecule (α2β2). This change, in turn, results in replacement of
the normal glutamic acid with valine at position 6 of the β-globin
chain and the formation of sickle Hb. Sickle cell anaemia (SCA) is
the homozygous state, where the sickle gene is inherited from both
parents. Other sickle cell disorders result from the co-inheritance
of the sickle cell gene with the gene of other abnormal haemoglobin such as Hb C, Hb D or HbO-Arab, giving rise to Hb SC disease, Hb SD disease or Hb SO-Arab disease respectively. Moreover,
the co-inheritance of the sickle gene with thalassaemia genes (β
0 or β + ) results in sickle-β 0 -thalassemia or sickle-β + -thalassaemia
respectively. In SCD, amino acid substitution causes HbS to polymerise intracellularly when deoxygenated, thus changing the biconcave discoid shape of red blood cells (RBCs) to sickle shapes.
Sickling is precipitated by hypoxia, extreme temperatures, dehydration, physical or emotional stress, menstruation and infection.
The sickled cells tend to have a shorter survival rate and plug vessels in microcirculation leading to acute syndromes such as vasoocclusive crises (VOCs), sickle chest syndrome, aplastic crisis and
sequestration crisis; in the long term these are followed by chronic
organ damage (Fonseca 2007; Ingram 1957).
Clinical features of SCD include pain episodes, anaemia of variable severity, organ damage and infection. Pain, however, is the
hallmark of SCD in general and SCA in particular and it is the
most important aspect of its clinical picture. All body organs are affected, or are at risk of being affected, by SCD. The complications
of most major organs such as the brain, lungs, liver and kidney are
relatively well known and described in the literature. Treatment
of dental complications, however, has not been well addressed.
Common dental complications described in SCD include caries
or cavities, tooth hypomineralisation, orofacial pain, neuropathy,
facial swelling, pallor of oral mucosa, malocclusions, infections,
pulpal necrosis, cortical erosions, medullary hyperplasia and abnormal trabecular spacings (Andrews 1983; Ballas 2014; Demirbas
Kaya 2004; Fonseca 2007; Friedlander 1980; Mendes 2011; Scipio
2001; Soni 1966; Taylor 1995). Studies have shown that individuals with SCD have a greater risk of developing a general or
dental infection, commonly of unknown origin, as compared to
controls; and these dental infections could, in turn, in some cases
be responsible for precipitating sickle cell crises (O’Rourke 1990;
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Rada 1987). Most providers know that dental complications such
as infections (gingivitis, periodontitis) and caries are factors that
precipitate VOCs. Dental infection through inflammatory mediators could potentially trigger or exacerbate an already existing
crisis leading to increased hospital admissions (Laurence 2013).

Description of the intervention
Dental treatment for people with SCD should be designed keeping
in mind both their general health and the possible impact of the
dental procedures on their pre-existing systemic condition. Prophylactic antibiotics are administered to prevent the precipitation
of VOCs or systemic infections as a result of dental infections or
surgical treatment procedures. Local anaesthetic, conscious sedation, anxiolytics and sedatives to alleviate anxiety are also used to
avoid the precipitation of stress or pain-related crises. Antidepressants, anticonvulsants and clonidine are used for treating neuropathic pain (Fonseca 2007; Piccin 2008). For dental procedures
requiring intravenous sedation or general anaesthesia, individuals are referred to hospitals with haematology expertise and care
is taken to keep the person well-hydrated and warm, with oxygen therapy administered during and immediately after the procedure. To correct malocclusion, orthodontic treatment is carried
out using light forces and increased periods of rest during tooth
movement, while monitoring bone response, pulpal health and
the systemic condition (Fonseca 2007; Rinchuse 2007; Zahrowski
2009).

taneously be a cause as well as an effect of disturbance in other
intricately linked systems (Wison Schaeffer 1999). A lack of understanding of this intimate relationship between oral and general
health among lay and medical people alike has led to the exclusion
of oral health as an important traditional clinical indicator of general health and well-being. This is prominently observed among
people with special needs and medically compromised conditions
(like SCD) who are not only predisposed to dental pathologies,
but whose treatment also needs special consideration. This results
in many of these people being refused treatment by dentists due
to fear of trans- and post-operative complications which they are
unable or unequipped to deal with. This could also be attributed
to lack of clinical guidelines, awareness and training or sufficient
information, research or data in the literature to enable healthcare providers to handle such cases confidently and successfully
(Laurence 2006; Passos 2012).
Haemoglobin disorders, having lost their regional specificity, are
now a global concern. In poorer countries, improved hygiene,
nutrition and public health ensure reduced levels of infant and
childhood mortality, which means more infants with SCD are
surviving and presenting for treatment later in life. This poses
a challenge to public health resources and the expertise of the
medical community in handling and treating them, prompting
the issue to be labelled as an “emerging global health burden”
(Edwards 2005; Reisine 1985; Weatherall 2010). It is the intention
of this review to comprehensively explore the literature and look for
clinically useful evidence for the treatment of dental complications
and thus improve the oral health-related quality of life (OHQoL)
of people with SCD.

How the intervention might work
Splenic function is reduced in people with SCD, thus reducing their immunity especially against encapsulated bacteria and
increasing their susceptibility to infection. Vaccinations against
Pneumococcus pneumoniae can prevent the most frequent systemic
complications in these individuals. By the same rationale, antibiotic prophylaxis before invasive dental surgical procedures is recommended to prevent local or systemic infections and the precipitation of crises in people with SCD. Conscious sedation, prescription of anxiolytics and scheduling of dental appointments during
chronic phases may alleviate stress and prevent treatment-related
sickle cell crises. Orthodontic treatment is carried out using light
forces and with appropriate intervals of rest in order to avoid or
minimize pain, crises or infections during the procedure (Alves
2006).

OBJECTIVES
The main objectives of this review are to assess methods to treat
dental complications in people with SCD. The terminology ’dental complications’ is used to represent all oral infections, diseases
and conditions affecting the teeth, jaws, orofacial region and associated structures, such as dental caries, periodontal disease, odontogenic infections, osteomyelitis, cellulitis, craniofacial deformities and malocclusion.

METHODS

Why it is important to do this review

Criteria for considering studies for this review

Oral health issues or dental problems can no longer be considered
as isolated, random, mutually exclusive occurrences, but instead
need to be seen as an integral part of a complex holistic physiological apparatus, where dysfunction in one system could simul-

Types of studies
Randomised controlled trials (RCTs) and quasi-RCTs.
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Types of participants
All children and adults diagnosed with SCD irrespective of phenotype, severity, age, gender and ethnic origin.

Types of interventions
We planned to consider any study which included one or more of
the following interventions being compared with either placebo,
no treatment or an alternative treatment in the treatment of dental
complications.
1. Management of dental pain using analgesics and alternative
techniques, e.g. acupressure, relaxation and Reiki.
2. Prevention of sickle cell crises during treatment (using preoperative analgesics, anxiolytics, conscious sedation and
prophylactic antibiotics).
3. Application of light forces, non-extraction mechanics and
modification of treatment according to bone and systemic
conditions during orthodontic therapy.
4. Early intervention and minimally invasive techniques for
caries management.

Types of outcome measures

Primary outcomes

1. Resolution or reduction in the severity of the condition (as
measured by)
i) decayed, missing, filled teeth (DMFT) index,
radiographic changes, salivary acid or streptococcus mutans
levels for dental caries
ii) gingival or plaque indices, probing depth, bone level
for periodontal diseases
iii) change in teeth or jaw positions, cephalometric
analysis, malocclusion indices (in case of malocclusions and
craniofacial deformities)
iv) visual analogue scale, dichotomy scale or Likert scale
for pain assessment
v) any other relevant measure reported

Secondary outcomes

1. Adverse incidents consequent to treatment, e.g. systemic
infections, impairment or loss of oral function, iatrogenic
damage during treatment like pulpal necrosis, root resorption or
bone loss
2. Sickle cell crises due to dental complications in individuals
with SCD
3. Health service utilisation
i) frequency of emergency department visits and hospital
admissions
ii) duration of hospitalisations

iii) consultations with practitioners
4. Quality of life (physical and social function, ability to fulfil
roles, life satisfaction) as measured using a validated scoring
system such as Health Status Survey Short Form (SF-36), the
Profile of Mood Status (POMS), Child Health QuestionnaireParent Report Form or any other
5. Economic effects (e.g. loss or change of job, number of days
off work or school, treatment cost)

Search methods for identification of studies
We attempted to identify all relevant studies regardless of language
and status of publication.

Electronic searches
We searched for relevant studies from the Cystic Fibrosis and
Genetic Disorders Group’s Haemoglobinopathies Trials Register using the term: dental AND (sickle cell disease OR
haemoglobinopathies general).
The Haemoglobinopathies Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of The Cochrane Library)
and weekly searches of MEDLINE. Unpublished work is identified by searching the abstract books of five major conferences:
the European Haematology Association conference; the American
Society of Hematology conference; the British Society for Haematology Annual Scientific Meeting; the Caribbean Health Research
Council Meetings; and the National Sickle Cell Disease Program
Annual Meeting. For full details of all searching activities for the
register, please see the relevant section of the Cochrane Cystic
Fibrosis and Genetic Disorders Group Module.
Date of latest search: 04 April 2016.
We also searched PubMed (www.ncbi.nlm.nih.gov/pubmed) and
Google Science (scholar.google.com/)
Date of latest search: 03 March 2016.
We also searched the following registries of ongoing clinical studies
from date of inception for evidence of unpublished studies and
protocols of published studies:
• ClinicalTrials.gov (ClinicalTrials.gov);
• WHO International Clinical Trials Registry Platform (
www.who.int/ictrp/search/en/);
• Literature in the Health Sciences in Latin America and the
Caribbean database (LILACS) (lilacs.bvsalud.org/en/);
• African Index Medicus (AIM 2002) (
indexmedicus.afro.who.int/)
• Index Medicus for South East Asia Region (
imsear.hellis.org/);
• Index Medicus for the Eastern Mediterranean Region (
www.emro.who.int/information-resources/imemr/imemr.html);
• Indexing of Indian Medical Journals (www.indmed.nic.in/).
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For more details of the individual search strategies, please refer to
the appendices (Appendix 2).
Date of latest search: 03 March 2016.
Searching other resources
We intended to scrutinize the reference lists of the identified studies
for additional citations and also to cross-check references from any
obtained studies to identify more studies. We contacted haematologists, experts in different fields of dentistry, organizations and researchers working in this field. We also contacted pharmaceutical
companies for information on unpublished and ongoing studies.

Data collection and analysis
No studies were available for inclusion. The following methods
will be employed should studies be included in future updates of
this review.

Assessment of risk of bias in included studies
Two review authors (PM, ABL) will independently assess the risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreement by discussion or by involving a
third assessor (LK).

1. Random sequence generation (checking for possible
selection bias)

For each included study, we will describe the method used to
generate the allocation sequence in sufficient detail to allow an
assessment of whether it should produce comparable groups. We
will assess the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.

Selection of studies
Two review authors (PM, SB) will independently assess for inclusion all the potential studies identified as a result of the searches. We
will resolve any disagreement through discussion or, if required,
we will consult a third person (ABL).
We will include studies published only in abstract form if they
otherwise satisfy the review’s inclusion criteria. We will contact the
authors of such studies if we require any additional information.
Data extraction and management
We will design a form to record any extracted data from eligible
studies. Two review authors (PM, LK) will independently extract
the following information from any included studies.
1. Methods: study design; total duration of study; study
location; study setting; withdrawals; and date of study.
2. Participants: number enrolled; mean age or age range;
gender; severity of condition; diagnostic criteria if applicable;
inclusion and exclusion criteria.
3. Interventions: description of intervention; comparison;
duration; intensity; content of both intervention and control
condition; and co-interventions.
4. Outcomes: description of primary and secondary outcomes
specified and collected, and at which time points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
We will resolve discrepancies through discussion or, if required,
we will consult a third or fourth person (SB, ABL). We will enter
the data into the Review Manager software and check for accuracy
(RevMan 2014). When information regarding any of the above is
unclear, we will attempt to contact authors of the original reports
to provide further details.

2. Allocation concealment (checking for possible selection
bias)

For each included study, we will describe the method used to
conceal the allocation to interventions prior to assignment and will
assess whether this allocation could have been foreseen in advance
of, or during recruitment, or changed after assignment. We will
assess the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or nonopaque envelopes, alternation; date of birth);
• unclear risk of bias.

3. Blinding

3.1. of participants and personnel (checking for possible
performance bias)
For each included study, we will describe the methods used, if
any, to blind study participants and personnel from knowledge of
which intervention a participant received. We will consider that
studies are at low risk of bias if they were blinded, or if we judge
that the lack of blinding would be unlikely to affect results. We
will assess blinding separately for different outcomes or classes of
outcomes. We will assess the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
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3.2. of outcome assessment (checking for possible detection
bias)
For each included study, we will describe the methods used, if any,
to blind outcome assessors from knowledge of which intervention
a participant received. We will assess blinding separately for different outcomes or classes of outcomes. We will assess methods used
to blind outcome assessment as:
• low risk of bias;
• high risk of bias;
• unclear risk of bias.
4. Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)

For each included study and for each outcome or class of outcomes, we will describe the completeness of data including attrition and exclusions from the analysis. We will state whether attrition and exclusions were reported and the numbers included in the
analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and
whether missing data were balanced across groups or were related
to outcomes. Where sufficient information is reported, or can be
supplied by the study authors, we will re-include missing data in
the analyses which we undertake. We will assess methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ’as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
In case of missing data we will take the following steps:
• if possible, contact the original investigators to request
missing data;
• make explicit any assumptions we make to deal with
missing data, for example, if we assume that the data are missing
at random, or if we assume that missing data have a particular
value such as a poor outcome;
• perform sensitivity analyses to assess how sensitive results
are to reasonable changes in the assumptions that are made;
• address the potential impact of missing data on the findings
of the review in the ’Discussion’ section.

• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
6. Other bias (checking for bias due to problems not covered
by (1) to (5) above)

For each included study, we will describe any important concerns
we have about other possible sources of bias. We will assess whether
each study was free of other problems that could put it at risk of
bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
7. Overall risk of bias

We will make explicit judgements about whether studies are at
high risk of bias, according to the criteria given in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
With reference to points 1 to 6 above, we will assess the likely
magnitude and direction of the bias and whether we consider it is
likely to impact on the findings. We will explore the impact of the
level of bias through undertaking sensitivity analyses
Measures of treatment effect
For dichotomous data (e.g. adverse effects), we will present results
as a summary risk ratio (RR) with 95% confidence intervals (CIs).
For continuous data (e.g. number of decayed, missing or filled
teeth), we will use the mean difference (MD) and 95% CIs if outcomes are measured in the same way between studies. We will use
the standardised mean difference (SMD) to combine studies that
measure the same outcome, but use different units of measurement.
We will calculate the events occurring more than once per person
as the number of counts and treated in the same way as continuous
outcome data. We will present the MD and compare the difference
in the mean number of events (standardized to a unit time period)
experienced by participants in the intervention group compared
with participants in the control group (Deeks 2011).

5. Selective reporting (checking for reporting bias)

For each included study, we will describe how we investigated the
possibility of selective outcome reporting bias and what we found.
We will assess the methods as:
• low risk of bias (where it is clear that all of the study’s prespecified outcomes and all expected outcomes of interest to the
review have been reported);

Unit of analysis issues
We will include cluster-randomised studies in the analyses along
with individually randomised studies. We will adjust their sample
sizes by methods using an estimate of the intra-cluster correlation
co-efficient (ICC) derived from the study (if possible), or from
another source. If we use ICCs from other sources, we will report
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this and conduct sensitivity analyses to investigate the effect of
variations in the ICC. If we identify both cluster-randomised studies and individually randomised studies, we plan to synthesise the
relevant information. We will consider it reasonable to combine
the results from both types of study if there is little heterogeneity
between the study designs and the interaction between the effect
of intervention and the choice of randomisation unit is considered
to be unlikely. We will also acknowledge heterogeneity in the randomisation unit and perform a separate meta-analysis. Therefore,
we will perform the meta-analysis in two parts.

Dealing with missing data
For included studies, we will note levels of attrition. We will explore
the impact of including studies with high levels of missing data
in the overall assessment of treatment effect by using a sensitivity
analysis. For all outcomes, we will carry out analyses (as far as
possible) on an intention-to-treat basis, i.e. we will attempt to
include all participants randomised to each group in the analyses,
and all participants will be analysed in the group to which they were
allocated, regardless of whether or not they received the allocated
intervention. The denominator for each outcome in each study
will be the number randomised minus any participants whose
outcomes are known to be missing. We will exclude studies with
more than 20% missing data. We will also perform sensitivity
analyses to assess how sensitive results are to reasonable changes in
the assumptions that we make.

Assessment of heterogeneity
We will assess methodological heterogeneity by examining the risk
of bias of any included trial. We will assess statistical heterogeneity
among studies by visually inspecting the forest plots and using
the Chi2 test and I2 statistic for heterogeneity with a statistical
significance level of P value < 0.10. For the interpretation of the I
2 values, we will use the following guidelines (Higgins 2011):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
If we identify substantial heterogeneity, we will report it and explore possible causes by subgroup analysis.

Assessment of reporting biases
If there are 10 or more studies in the meta-analysis, we will investigate reporting biases (such as publication bias) using funnel plots.
We will assess funnel plot asymmetry visually and if this suggests
there is asymmetry, we will perform exploratory analyses to investigate this as detailed in the Cochrane Handbook for Systematic
Reviews of Interventions (Sterne 2011).

Data synthesis
We will carry out statistical analysis using the Review Manager
software (RevMan 2014). We will use a fixed-effect meta-analysis
for combining data where it is reasonable to assume that studies are
estimating the same underlying treatment effect, i.e. where studies
are examining the same intervention, and the study populations
and methods are judged sufficiently similar. If there is clinical heterogeneity sufficient to expect that the underlying treatment effects will differ between studies, or if substantial statistical heterogeneity is detected and a pooled treatment effect across studies is
still considered clinically meaningful, we will use a random-effects
meta-analysis to produce an overall summary and discuss the clinical implications of treatment effects differing between studies. If
we use a random-effects analysis, we will present the results as the
pooled treatment effect with 95% CIs and the estimates of I2 . If
the pooled treatment effect is not clinically meaningful, we will
not combine studies.

Subgroup analysis and investigation of heterogeneity
If we identify substantial heterogeneity, we will investigate it using
subgroup analyses. We will consider whether an overall summary
is meaningful, and if so we will use a random-effects analysis to
produce it. We plan to carry out the following subgroup analyses:
• male versus female participants;
• different ages paediatric (up to 18 years of age) versus adult
(18 years and over);
• different types of SCD.
We will assess subgroup differences using interaction tests available
within the Review Manager software (RevMan 2014). We will
report the results of the subgroup analyses quoting the Chi2 test
and P value, and the interaction test I2 value.

Sensitivity analysis
We will perform sensitivity analyses for aspects of the review that
might affect the results; for example, where there is a risk of bias
associated the included studies. We will undertake analysis of the
primary outcome separately for studies with a low risk of bias
and a high or unknown risk of bias for allocation concealment.
We will explore the impact of including studies with high levels
of missing data in the overall assessment of treatment effect and
also to assess how sensitive results are to reasonable changes in the
assumptions that are made on missing data. We will also carry
out a sensitivity analysis to explore the effects of random-effects
analyses for outcomes with statistical heterogeneity. We will also
conduct sensitivity analyses to investigate the effect of variations
in any ICCs we have used.
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Summary of findings table
We will create a ’Summary of findings’ table for each comparison
using the following outcomes.
1. Resolution or reduction in the severity of the condition
2. Adverse incidents consequent to treatment
3. Health service utilisation
We will use the five GRADE considerations (study limitations,
consistency of effect, imprecision, indirectness and publication
bias) to assess the quality of a body of evidence as it relates to the
studies which contribute data to the meta-analyses for the prespecified outcomes. We will use methods and recommendations
described in section 8.5 and chapter 12 of the Cochrane Handbook
for Systematic Reviews of Interventions using GRADEpro software
(Higgins 2011; Schünemann 2011). We will justify all decisions
to down- or upgrade the quality of studies using footnotes and
we will make comments to aid the reader’s understanding of the
review where necessary.

Despite undertaking an extensive search of the literature (electronic searching, handsearching and identifying ongoing trials),
no randomised controlled trials (RCTs) were identified which met
the inclusion criteria for this review.

Potential biases in the review process
This Cochrane review contains no studies and as such, no risk
of bias could be evaluated. it is possible that trials with negative
results may have remained unpublished. In spite of the extensive
search carried out, no RCTs were available for inclusion. The main
limitation of this Cochrane review is the paucity of evidence for
treatment of dental complications in people with sickle cell disease
(SCD).

Agreements and disagreements with other
studies or reviews
RESULTS

Description of studies

Results of the search
The searches did not identify any RCTs or quasi-RCTs eligible for
inclusion in this Cochrane review (nor any that were potentially
eligible); we were not able to identify any ongoing studies.

Risk of bias in included studies
The searches did not identify any RCTs or quasi-RCTs eligible for
inclusion in this Cochrane review (nor any that were potentially
eligible).

Effects of interventions
The searches did not identify any RCTs or quasi-RCTs eligible for
inclusion in this Cochrane review (nor any that were potentially
eligible), nor were we able to identify any ongoing trials.

DISCUSSION

Summary of main results

Due to the absence of evidence from RCTs or quasi-RCTs, we
were unable to compare our results with other published systematic reviews or excluded studies. During our search, we did identify a small body of mid-level evidence derived from observational
studies such as cohort, case-control and cross-sectional sectional
studies, but most of these report incidences or prevalences of dental diseases and their impact on people with SCD compared to
healthy controls and do not investigate any intervention for treating these complications. Furthermore the bulk of the evidence in
this area is of low level, derived mostly from retrospective studies,
case reports and expert opinion articles which consist predominantly of descriptive narrations of the pathological changes in the
oral-dental-craniofacial region, general principles of treatment and
specific interventions in cases encountered. A condensed summary
of available information derived from these sources follows.
Two studies recommended that if individuals are experiencing a
vaso-occlusive crisis, only emergency relief of pain and infection is
indicated. Infections should be treated with antibiotics and definitive treatment postponed until the crisis subsides (Hammersley
1984; Rouse 1979). A retrospective study reported successfully
performing outpatient procedures without any complications in
people with SCD by administering 2% lignocaine with 1:100,000
epinephrine (Stanley 2013). Acetaminophen or codeine were recommended for post-operative pain control, but aspirin was not
recommended due to its possible adverse effect on platelet function
resulting in increased bleeding, acid-base balance and bone marrow suppression (Smith 1986). In cases of osteomyelitis in the posterior mandibular region, treatment may include sequestrectomy,
curettage, debridement, corticotomy and resection of mandible
and affected muscles with appropriate antibiotic coverage and following the surgical principles recommended for people with SCD
(Hammersley 1984; Lawrenz 1999; Shroyer 1991). The 2014 evidence-based expert panel report on SCD recommends using red
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blood cell transfusion to bring preoperative haemoglobin levels to
10 g/dL prior to any surgical procedures involving general anaesthesia (Yawn 2014).
Avascular pulpal necrosis in clinically intact teeth was a common
finding in people with SCD; hence, a routine evaluation of pulp
in clinically intact teeth was recommended (Costa 2013). Root
canal therapy must be carried out to satisfactory technical standard
and antibiotic prophylaxis may be required; this therapy may also
cause a sickle cell crisis (Gregory 1994).
A study has reported that 30.1% of individuals with SCD had
indications for mandatory orthodontic treatment as compared to
only 2.7% of the controls (Costa 2013). Orthodontic treatment
in people with SCD was considered to be elective (Sams 1990);
however successful treatment with fixed appliances in conjunction
with extractions and extraoral orthopedic appliances has been reported (Oluwatosin 2009; Pithon 2011).
Prevention of dental complications is considered the best approach in people with SCD. It is recommended that periodic dental screening should be provided as part of their general physical
examination. Incorporating fluorides, maintaining oral hygiene,
routine dental visits and treating dental issues as soon as they are
detected are measures which can reduce complications (Demas
1988; Javed 2013; Rouse 1979).

AUTHORS’ CONCLUSIONS

Implications for practice
This systematic review did not identify any RCTs or quasi-RCTs
to guide treatment of dental complications in people with SCD.
Accordingly, we are unable to evaluate the effects of any interventions. In the absence of high quality evidence, clinicians need to
use their clinical judgement and refer to lower level evidence (e.g.
observational studies, case reports, expert opinion) for selecting
the best and most suitable form of intervention for treating the
dental complications in people with SCD.

Implications for research
This Cochrane review has identified the need for well-designed,
adequately powered RCTs to assess the effectiveness of treatments
for dental complications in people with SCD.
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DATA AND ANALYSES
This review has no analyses.

APPENDICES

Appendix 1. Glossary of terms

Term

Explanation

aplastic crisis

temporary cessation of red cell production

exon

portion of a gene that codes for amino acids

gingivitis

inflammation of the gingiva as a response to bacterial plaque on adjacent teeth

homozygous

having identical pairs of genes for any given pair of hereditary characteristics

hypomineralization

a condition affecting the enamel of the permanent teeth and characterized by a deficiency of minerals; normal
enamel is white and very hard, but hypomineralized enamel is creamy, yellow or brown in colour and is chalky
in texture. As a result teeth look different in appearance, they also undergo wear and are at higher risk of
developing decay

hypoxia

this is when the body doesn’t have enough oxygen

intracellular

within a cell

malocclusion

a ’poor bite’, misaligned teeth between the top and bottom jaws

morphology

the form and structure of an organism or any of its parts

odontogenic

of, or relating to, the formation and development of teeth

oral mucosa

the mucous membrane lining the inside of the mouth, including lining on the gums, the palate, the lip, the
cheek, the floor of the mouth and other structures

orofacial

relating to the mouth and face

osteomyelitis

inflammation of the bone marrow and adjacent bone

periodontitis

a serious gum infection that damages the soft tissue and destroys the bone that supports your teeth; if inflammation of the gum tissue (gingivitis) is not treated periodontitis can develop

Treatment of dental complications in sickle cell disease (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

13

(Continued)

polymerize

a process through which relatively small molecules, called monomers, combine chemically to produce a very
large chainlike or network molecule, called a polymer

sequestration crisis

a condition affecting people with sickle cell anaemia which results from the trapping of large amounts of red
cells in the spleen and sometimes in the liver so they are withdrawn from the blood in circulation leading to a
sharp drop in haemoglobin levels

vaso-occlusive

relating to, resulting from, or caused by occlusion of a blood vessel

Appendix 2. Multiple databases search strategy

SEARCH SITE

1

Date of search:
Type of Search
From inception to

Google Scholar
03 March 2016
(
scholar.google.com/)

Advanced

Keywords used

allintitle:
dental trial

sickle 0

allintitle: sickle trial

2

WHO ICTRP
(www.who.int/
ictrp/search/en/)

03 March 2016

03 March 2016

3

ClincialTrials.gov
03 March 2016
(ClinicalTrials.gov)

Basic

Advanced

Basic

Results

257

Relevant RCTs from results

0

0

allintitle: sickle den- 57
tal

0

sickle dental

0

0

Sickle oral

0

0

Sickle
cell 0
AND dental AND
treatment
Sickle cell AND oral
AND treatment

0

Sickle cell
dental oral

AND 0

0

Sickle cell
dental

AND 1

0

Sickle
cell 1
AND dental AND
treatment

0

“sickle cell” AND 0
“dental”

0
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(Continued)

4

LILACS
(lilacs.bvsalud.org/
en/)

03 March 2016

Advanced

Sickle cell, dental 0
treatment

0

03 March 2016

Basic

Sickle dental

17

0

Sickle dental trial

0

0

03 March 2016

5

African
Index 03 March 2016
Medicus
(
indexmedicus.afro.who.int/)

Advanced

Basic

Sickle cell AND 110
dental treatment

0

Sickle cell AND 0
dental AND trial

0

Sickle cell
dental

0

AND 0

Sickle and dental

03 March 2016

Advanced

“sickle cell”
“dental”

0

0

and 0

0

6

IMSEAR
(imsear.hellis.org/)

03 March 2016

Basic

“sickle” and “ran- 392
domized controlled
trial”

0

7

IMEMR
03 March 2016
(
www.emro.who.int/
informationresources/imemr/
03 March 2016
imemr.html)

Basic

Sickle cell
dental

0

Advanced

“sickle cell”
“dental”

8

IndMED
03 March 2016
(
www.indmed.nic.in/)

Basic

Sickle AND dental

9

Pubmed
03 March 2016
(
www.ncbi.nlm.nih.gov/
pubmed)

Advanced

Sickle cell
dental

AND 0

Sickle and dental
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0

and 0

0

2

AND 167

0

0
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